Close this search box.

Investments in digital, AI tech will be part of Takeda’s return-to-growth program

ARTICLE | Finance

Pharma seeking efficiencies, agility as it looks to boost profits in 2025 and beyond

By Paul Bonanos, Director of Biopharma Intelligence

May 10, 2024 6:37 PM UTC

Deepened commitments to data and artificial intelligence are part of a program Takeda is implementing to spur growth and improve margins, the pharma said as it presented full fiscal-year earnings Thursday.

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) said its new, unnamed program is meant to improve efficiency and organizational agility, following what President and CEO Christophe Weber called a “well-managed but tough year” during its earnings call. Takeda’s fiscal 2023 ended March 31, 2024…